Effects of bisphosphonates on matrix mineralization

Area of Science:

• Bone biology and osteoporosis research
• Pharmacological interventions for bone diseases
• Mineralization and bone quality assessment

Background:

• Bone strength depends on tissue volume, microarchitecture, and degree of mineralization.
• Osteoporosis involves bone loss and microarchitectural deterioration.
• Therapeutic agents aim to preserve bone, increase matrix volume, or enhance mineralization.

Purpose of the Study:

• To investigate if alendronate (ALN) treatment increases the degree of bone mineralization (DMB) in postmenopausal osteoporotic women.
• To determine if increased DMB contributes to the observed increases in bone mineral density (BMD) and reduced fracture incidence.

Main Methods:

• Quantitative microradiography on transiliac bone biopsies from 53 postmenopausal women treated with ALN or placebo (PLA).
• Dual-energy X-ray absorptiometry (DXA) for lumbar spine BMD.
• Histomorphometry and activation frequency measurements.

Main Results:

• ALN treatment significantly increased mean DMB in both compact and cancellous bone after 2 and 3 years compared to PLA.
• ALN increased DMB by 7.3-11.6% (p<0.001) depending on bone type and duration.
• DMB increases correlated with BMD increases, suggesting DMB accounts for much of the BMD gain.

Conclusions:

• Alendronate treatment prolongs secondary mineralization, increasing the degree of bone mineralization.
• Enhanced DMB is a key mechanism contributing to ALN's efficacy in improving bone strength and reducing fractures.
• Quantitative microradiography is crucial for assessing the mineral dimension of bone quality.